The 274 recruited COVID-19 patients were stratified into two groups: the anti-MDA5 Ab negative group (<5.0 U/mL) and the positive group (≥5.0 U/mL) as the commercial kit suggested. This evidence concerns the gene IFIH1 and COVID-19.